Related Experiment Videos
Oncogenesis by mutations in anti-oncogenes: a view
W Den Otter1, J W Koten, B J Van der Vegt
1Department of Pathology, Academisch Ziekenhuis, Utrecht, The Netherlands.
Anticancer Research
|March 1, 1990
Summary
Cancer development typically requires four mutations in anti-oncogenes, challenging the 2-hit model. This finding helps explain tumor formation and timing across different organs.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Oncogenesis results from accumulating gene mutations affecting oncogenes and anti-oncogenes.
- Anti-oncogenes normally inhibit oncogene expression; defects allow oncogene activation.
- Tumor cells often exhibit homozygous defects in anti-oncogenes.
Purpose of the Study:
- To calculate the number of anti-oncogenes involved in malignant tumor cell genesis.
- To reconcile theoretical cancer models with observed tumor incidence.
Main Methods:
- Mathematical modeling of oncogenesis, starting with a simplified model.
- Application of calculations to more complex oncogenesis scenarios.
- Comparison of model predictions with clinical and pathological data (e.g., MEN1-syndrome).
Main Results:
- Calculations suggest four anti-oncogene mutations are typically required for oncogenesis in adults.
- This contrasts with the 2-hit model, which overestimates de novo tumor cell formation.
- Cell proliferation kinetics and organ development timing influence tumor manifestation age.
Conclusions:
- Four recessive anti-oncogene mutations, likely involving two loci, are implicated in oncogenesis.
- Inherited anti-oncogene mutations can lead to different tumor types based on organ of origin.
- Pre-malignant cells with fewer mutations may have a growth advantage, driving proliferation until the full mutation set is achieved.